cyrilzakka/clinical-trials huggingface dataset:
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Primary Objectives:

* Delineate the short-term appetite of patients who undergo minimally-invasive proximal gastrectomy (MIPG) and compare them with those of patients with gastric and gastroesophageal adenocarcinoma who undergo total gastrectomy (MITG). We hypothesize that MIPG is associated with better postoperative appetite levels compared to MITG, which would result in improved nutritional status and maintained body weight after surgery.

Secondary Objectives:

* Assess patient-reported outcomes (PROs) and nutrition measures. We will use the MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI) questionnaire with additional three experimental question items ("PRO questionnaire") to collect preoperative and postoperative patient-reported outcomes (PROs) of QoL and check fasting ghrelin levels to correlate them with reported appetite levels. We will also retrospectively investigate factors associated with improved QoL after surgery, safety of MIPG and MITG, and oncological outcomes after MIPG and MITG.

Eligibility Criteria:
Inclusion Criteria:

1. Able to speak and read English or Spanish (for patients enrolled at MD Anderson and Mayo Clinic), English or Korean (for patients enrolled at Yonsei), and English or Japanese (for patients enrolled at Keio)
2. Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
3. Age ≥ 18

Exclusion Criteria:

1. Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
2. Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
3. Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
4. Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)
Measurement of Serum Potassium Rate During Accidental Hypothermia.

Serum Potassium Rate (PR) is a key indicator for medical management of patients with accidental hypothermia particularly for hypothermia related cardiac arrest (CA).

Experts recommend a cut-off value for PR of 12 mmol/l for all hypothermic victims and 8 mmol/l for avalanche casualties. Any patient presenting a PR lower than the cut-off value should be considered for Extracorporeal Rewarming. This therapeutic strategy is vital for patient survival.

However, there is no consensus about what type of vessels should be punctured in order to obtain an accurate potassium rate and what type of measurement technics should be used to measure this potassium rate.

The investigators hypothesize that potassium rate in these patients will differ by 1 mmol/l in blood samples collected from a peripheral vein in contrast to a central vein.

The investigators study is a prospective observational, multicentre study.


Eligibility Criteria:
Inclusion Criteria:

* Hypothermia related cardiac arrest
* Age \> 18 years
* Core temperature \< 30° C measured in oesophagus at hospital admission

Exclusion Criteria:

* Age \< 18 years
* Known condition of pregnancy or breastfeeding women
* Evidence of trauma-related cardiac arrest
* Cardiac arrest in which reanimation is not justified (frozen body, final stadium of an incurable disease, advance health care directive)
Caremap: A Digital Personal Health Record for Complex Care Coordination

This study will implement a new mobile application ('app') called Caremap to improve care coordination for patients with complex health needs. The goal is to pilot test the mobile app with patients/families and clinic doctors to gather input on how well the app works and how to make it better. Investigators plan to enroll up to 40 participants from Duke University for this study. The study is sponsored by Duke's Institute for Health Innovation.


Eligibility Criteria:
Inclusion criteria for parents/caregivers of children/youth with special health care needs (CYSHCN):

* Adult parent/legal guardian (age 18 or older) of a CYSHCN
* Established care for their child/youth at Duke Pediatrics Primary Care or Duke Children's Cystic Fibrosis clinic (established = one or more completed visits in the past 12 months at the clinic)
* High level of complex medical needs that could benefit from additional care coordination support (determined by clinical provider at the pilot site)
* Primary provider enrolled in the study as a provider participant/clinical provider site champion
* Active Duke MyChart (online EHR patient portal) account
* Full proxy access activated/enabled for parent to the child/youth's medical record in Epic
* Apple iOS device compatible with Caremap app requirements at time of consent

Inclusion criteria for adult patients with multiple chronic conditions (MCC):

* Adult patient (age 18 or older) with MCC
* Established care for the patient at Duke Geriatrics clinic or Duke Pulmonary Transplant clinic (established = one or more completed visits in the past 12 months at the clinic)
* High level of complex medical needs that could benefit from additional care coordination support (determined by clinical provider at the participating clinic site)
* Primary provider enrolled in the study as a provider participant/clinical provider site champion
* Active Duke MyChart (online EHR patient portal) account
* Apple iOS device compatible with Caremap app requirements at time of consent

Inclusion criteria for clinical provider site champions (to participate in interviews and quantitative provider-reported surveys):

* Currently practicing at Duke Health
* Primary site of work is participating clinic site

Exclusion criteria:

* Non-English speaking
* Living in long-term, congregate settings - e.g., living in institutionalized settings such as long-term care facility, nursing/long-term rehab facilities
* Lacks requisite technology to access and use mobile app (e.g., device/tablet/smartphone, home internet, active Epic MyChart account)
* Lack of decision-making capacity (clinician-determined; e.g., patients with advanced dementia)
A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.


Eligibility Criteria:
Inclusion Criteria:

* patients with T3 and T4 stage NSCLC；
* available preoperative chest CTE within two weeks of surgery

Exclusion Criteria:

* inadequate imaging quality resulted from breathing artifact;
* without regularly follow-up information on recurrence location and time
Clinical Database and Biobank of Patients With Gynecologic Neoplasms

The database and biobank establishment started in 1997 in our institute. However, the sample size was too small with respect to our clinical and fundamental scientific research's requirement. Thus the Chinese gynecological oncology study (GOS) group was established to create a large multicentre database and biobank of patients with gynecologic diseases.

The database contains clinical and epidemiologic information about patients with gynecologic neoplasms, such as cervical carcinoma, ovarian carcinoma, etc. With the data gathered from this database, the investigators could further demonstrate the etiology, risk factor, clinical treatment, and other aspects of the complicated gynecologic diseases. The cervical cancer database v1.10 including more than 10,000 cases and more than 200 variables has been established.

The biobank collects blood, fluids, tissue samples, and related clinical data from consenting patients with gynecologic neoplasms, such as cervical cancer, ovarian cancer, endometrial cancer, choriocarcinoma, uterine myoma, endometriosis. Besides, blood samples of population-based healthy people with informed consent are also collected.

Eligibility Criteria:
Inclusion Criteria:

* patients with informed consent;
* patients with gynecologic diseases;
* patients with intact clinical and pathological information

Exclusion Criteria:

* not included in the inclusion criteria
Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning

Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning.

The study aims to investigate the Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial

Eligibility Criteria:
Inclusion Criteria:

* • Patients with symptomatic acute aluminum phosphide poisoning

Exclusion Criteria:

* • Pregnant and lactating women

  * Asymptomatic patients with history of acute aluminum phosphide exposure.
  * Patients with ingestion or exposure to other substances in addition to aluminum phosphide.
  * Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).
  * Patients with previous medical intervention (had gastric lavage in any medical center before admission).
  * Patients with disturbed consciousness level
  * Patients with post cardiac arrest cases
Application of PDCA Circular Management to Improve Critical Thinking Skills of ICU Nurses Within Five Years of Employment

Choose about 100 low -age nurses who have been in the ICU in 2022, and conduct a scoring score of the survey and critical thinking skills through the schedule. Based on the survey and scoring results ,Formulate the PDCA circular management process and conduct a judgment of critical thinking skills after intervention.To compare the critical thinking skills survey score before and after.

Through the countermeasure 1-ABC rescue training: Clarify the positions and perform their duties; Countermeasure 2-Advanced Life Support (ACLS) training: Clear division of labor and strengthen the cooperation Tune; Countermeasure 3-Objective Structural Clinical Test (OSCE Exam): Objective, orderly, and organized assessment. The framework and group competitions are evaluated to promote teaching and other measures.The comparison experimental objects use the data of the two questionnaires before and after the PDCA cycle management. Explore the application effect of PDCA circular management within five years of employment.

Eligibility Criteria:
Inclusion Criteria: (1) ICU nurse within five years of joining the ICU

(2) Voluntary participation in this study.

-

Exclusion Criteria:(1) Clinical nurses who have worked for more than 5 years

(2) Involuntary participation in this study.

-
Ragweed-SPIRE Follow-On Study

The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.


Eligibility Criteria:
Inclusion Criteria:

° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006

Exclusion Criteria:

* Subject or Investigator have been informed of treatment received in Study TR006
* Subjects with significant allergy to animal dander
* Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies
* History of recurrent acute sinusitis or chronic sinusitis
* Received treatment with an investigational drug within 4 weeks of Screening
* Unable to understand study requirements or unable to communicate clearly with Investigator
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206

A feasibility study of neoadjuvant chemotherapy (NAC) followed by interval cytoreductive surgery (ICS) and postoperative chemotherapy for stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas.

The purposes are to assess the safety and efficacy of the treatment starting with NAC and to know whether we can accurately diagnose these advanced carcinomas by imaging studies, cytologic findings and tumor markers without staging laparotomy or laparoscopy. Fifty-six patients with advanced mullerian carcinomas will be recruited to the study. After confirmation of diagnosis by laparoscopic inspection and biopsies, patients undergo 4 cycles of chemotherapy as NAC followed by ICS and additional 4 cycles of postsurgical chemotherapy. The primary endpoint is proportion of clinical complete remission after accomplishment of the protocol treatment and the major secondary endpoint is positive predictive value of diagnosis before laparoscopy regarding tumor origin, histology and stage. Based on the result of this study, we will conduct a phase III study to compare the treatment starting with NAC and primary cytoreductive surgery followed by postsurgical chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Stage III or IV müllerian carcinoma by prelaparoscopic clinical findings including imaging studies (CT, MRI or ultrasonography)
* Cytology of ascites, pleural effusions, or fluids obtained by tumor centesis
* Malignancies of other origins, such as breasts and digestive tract, should be excluded by endoscopy, opaque enema, or ultrasonography when these malignancies are suspected from symptoms, physical examinations or imaging diagnosis.
* CA125\>200U/ml and CEA\<20ng/ml.
* Clinically deemed to be a candidate for debulking surgery without evidence of brain, bone, bone marrow metastases, multiple lung, or multiple liver metastases
* Presence of at least one measurable lesion
* Previously untreated for these malignancies and no history of treatment with chemotherapy or radiotherapy even for other diseases
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3,
* Adequate bone marrow, hepatic, renal, cardiac and respiratory functions, and
* Written informed consent.

Exclusion Criteria:

* Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ
* Pregnant or nursing
* Severe mental disorders
* Systemic and continuous use of steroidal drugs
* Active infections
* Uncontrolled hypertension
* Diabetes mellitus, uncontrolled or controlled with insulin
* History of cardiac failure, unstable angina, myocardial infarction within 6 months prior to the registration
* Liver cirrhosis or bleeding tendency contraindicating debulking surgery
* Intestinal occlusion necessary for surgical treatment
* Hypersensitivity to alcohol
Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus

This study examined the acceptability and feasibility of using a simplified regimen of medical abortion in Armenia and Azerbaijan. It was hypothesized that home use of mifepristone and misoprostol, and buccal administration of misoprostol, would be both acceptable to women and efficacious.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Good general health
* Living or working close to the study site
* Intrauterine pregnancy less than 64 days gestation
* Willing and able to sign consent forms
* Eligible for medical abortion according to the clinician's assessment
* Ready access to a telephone and emergency transportation
* Willing to provide an address and/or telephone number for purposes of follow-up
* Agree to comply with the study procedures and visit schedule

Exclusion Criteria:

* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass
* IUD in place (IUD must be removed first)
* Chronic renal failure
* Concurrent long-term corticosteroid therapy
* History of allergy to mifepristone, misoprostol or other prostaglandin
* Hemorrhagic disorders or concurrent anticoagulant therapy
* Inherited porphyrias
* Other serious physical or mental health conditions
Atlas Predicted DBS Settings in Essential Tremor

Programming Deep Brain Stimulation for the treatment of Essential Tremor can be a time intensive process. Using an atlas created using functional tremor responses in the operating room to determine the optimal settings would lead to a faster response for the patient and improved quality of life.


Eligibility Criteria:
Inclusion Criteria:

Seleced for DBS of the VIM nucleus at Vanderbilt Medical center Diagnosis of essential tremor

Exclusion Criteria:

Unable to use the patient handheld programmer
Piezo-surgery Technique and Intramuscular Dexamethasone Injection to Reduce Postoperative Pain After Impacted Mandibular Third Molar Surgery

The purpose of my study is to test the effect of using piezosurgery and dexamethasone injection in the surgical extraction of impacted mandibular third molars, on Postoperative Pain.

Background: Third molar surgery is the most common procedure performed in oral and maxillofacial surgery practice.

This procedure is always associated with varying degrees of postoperative pain and swelling that may have a social impact. Traditionally, rotating instruments like burs have been used for osseous surgery.

Piezosurgery is a novel technique introduced to overcome the disadvantages associated with the conventional rotatory technique. Corticosteroids administration before or after the extraction of third molars is an efficient way to minimize postoperative pain due to their strong anti-inflammatory activity.

Many researchers conducted studies comparing the piezosurgery technique with conventional rotatory technique, regarding postoperative pain and working time, or studies comparing the conventional method with or without dexamethasone injection. Only one recent study (Nov 2018), conducted by Gümrükçü Z. et al. has compared Piezosurgery and dexamethasone injection in third molar surgery, but without evaluating the combined effect of these two techniques on postoperative pain.

Objectives: The objective of this study is to assess the effects of piezosurgery technique and intramuscular dexamethasone injection on postoperative pain in impacted third molar surgery.

Methods: The study design is a randomized controlled clinical trial: 80 patients with mandibular third molar impaction, indicated for surgical extraction should be treated randomly using either the piezosurgery or the conventional rotatory technique, and with or without intramuscular dexamethasone injection. Postoperative pain will be assessed using a visual analog scale (VAS) on days 1, 3, and seven postoperatively.

The differences in Post-operative pain within and between study groups (4 groups) will be tested using repeated measures of analysis of variance (ANOVA) or Friedman tests. Differences in working time among the three techniques will be assessed using a repeated measure of ANOVA. All statistical tests will be two-sided, and the significant level will be set at 0.05. All the analysis will be conducted using the Statistical Package for Social Sciences (SPSS) software version 22.

Eligibility Criteria:
Inclusion Criteria:

* Age from 15 to 30 years,
* Having mandibular impacted third molars,

Exclusion Criteria:

* Heavy smokers (≥20 cigarettes),
* Uncontrolled systemic conditions,
* Infection of the surgery site,
* Psychological problems,
* History of allergy to dexamethasone, amoxicillin, or acetaminophen.
Analysis of Remote-ischemic Preconditioning Effects on Kidney Function

Patients with impaired renal function are at elevated risk for development of acute kidney injury (AKI). AKI is associated with increased risk for cardiovascular morbidity and mortality. Effective AKI prevention strategies are needed. Remote ischemic preconditioning (RIPC) is a novel and successful strategy to attenuate contrast medium induced AKI in patients undergoing elective coronary angiography.

The retrospective RenPro-TAVI Trial was designed to test the hypothesis whether remote ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter aortic valve implantation (TAVI).

Patients with impaired renal function undergoing TAVI will be evaluated in respect whether they received remote ischemic preconditioning before the procedure or not. This study will give insight if RIPC might be beneficial in these patients.


Eligibility Criteria:
Inclusion Criteria:

* age \>= 18 years
* impaired renal function (baseline eGFR of \<60 ml/min)
* high INTEGER risk score \> 11
* high EuroSCORE (European system for cardiac operative risk evaluation)

Exclusion Criteria:

* severe renal impairment (eGFR \<15 ml/min and/or in chronic dialysis)
* recent (\<=30 days) contrast media exposure
* patients enrolled in concomitant studies
* fertile women
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment

comparing the effect of using sildenafil citrate and LMWH in treatment of cases of IUGR due to placental insufficiency

One hundred pregnant women with documented intrauterine growth restriction due to placental insufficiency at 28-35 weeks of gestation will be distributed into two groups:

* Group S: 50 women will receive Sildenafil citrate 25 mg tab 3 times daily.
* Group H: 50 women will receive single dose of LMWH subcutaneous daily.

Both groups will undergo strict fetal surveillance in the form of:

Umbilical artery Doppler (UAD) is the primary surveillance tool in the FGR fetus:

middle cerebral artery (MCA) Doppler, ultrasound for (AC, EFW, and deepest vertical pocket (DVP) for amniotic fluid) and non stress test and Biophysical profile (BPP)

Eligibility Criteria:
Inclusion Criteria:

* Maternal age between 20-35 years.
* Being at a gestational age 28-35wks.
* Singleton pregnancy.
* Fetal growth restriction diagnosed by ultrasound with estimated fetal weight below the 10th percentile, and/or fetal abdominal circumference at or below the tenth percentile.

Exclusion Criteria:

* Maternal age less than 20 years or more than 35 years.
* Undetermined gestational age.
* Multiple gestation.
* Chronic diseases with pregnancy e.g. Chronic hypertension, diabetes type 1 or 2.
* Etiologies of FGR other than placental insufficiency as fetal malformations, aneuploidy or infections.
* Suspected fetal compromise requiring emergency delivery.
* Any contraindication to the use of sildenafil e.g. known significant maternal cardiac disease, left ventricular outflow tract obstruction, concomitant treatment with nitrates or previous allergy to sildenafil.
* Any contraindication to the use of LMWH e.g. known bleeding disorder, active antenatal bleeding or at increased risk of major hemorrhage (e.g. placenta praevia), thrombocytopenia, severe renal or hepatic disease.
* Drug or alcohol abuse.
* Patient refusing to participate in the study or unable to consent.